continuous infusion
Recently Published Documents


TOTAL DOCUMENTS

3739
(FIVE YEARS 554)

H-INDEX

99
(FIVE YEARS 12)

2022 ◽  
Vol 43 (2) ◽  
pp. 827-840
Author(s):  
Rochelle Gorczak ◽  
◽  
Marilia Avila Valandro ◽  
Bibiana Welter Pereira ◽  
Thaline Segatto ◽  
...  

Dipyrone is an effective analgesic for managing moderate or severe postoperative pain and can be used alone for mild pain or in combination with other analgesics for any type of pain. This study aimed to examine the administration of dipyrone by continuous infusion (CI) as an adjuvant analgesic in the intraoperative period for bitches undergoing elective ovariohysterectomy (OH) and its effect on these patients’ cardiorespiratory parameters. Twenty bitches underwent an elective OH procedure. The pre-anesthetic agent was a combination of acepromazine and morphine. Propofol was used to induce anesthesia, and isoflurane was used for maintenance. Subsequently, the animals were randomly allocated into two groups: the dipyrone group (DG) received a bolus dose of dipyrone (25 mg kg-1) by CI at a rate of 10 mg kg-1 h, and the control group (CG) received a bolus dose and a CI of 0.9% NaCl solution, both groups at a rate of 5 mL kg-1 h. The parametric variables were analyzed by ANOVA, followed by Tukey's test (p<0.05). The paired t-test (p<0.05) was used for comparison between the groups. Statistical differences were observed for heart rate, systolic, diastolic, and mean arterial pressure, respiratory rate, and blood glucose between the periods in both groups. There were differences only in the basal values of MAP between the groups; however, most values remained within the physiological range for the species. Using the drug as an adjuvant to anesthesia did not alter cardiorespiratory parameters, and it can be used as an adjuvant in analgesia during the intraoperative period of OH.


2022 ◽  
Vol 9 ◽  
Author(s):  
Pascal André ◽  
Léonore Diezi ◽  
Kim Dao ◽  
Pierre Alex Crisinel ◽  
Laura E. Rothuizen ◽  
...  

Introduction: Broad-spectrum beta-lactams are commonly prescribed for empirical or selective treatment of bacterial infections in children with malignancies. In the immunocompromised, appropriate concentration exposure is crucial to ensure antimicrobial efficacy. Augmented renal clearance (ARC) is increasingly recognized in this population, and raises concern for unmet concentration targets. We conducted a retrospective evaluation of meropenem and piperacillin exposure in our hospital's pediatric hematology-oncology patients.Materials and Methods: We compared trough levels of meropenem and piperacillin in a cohort of unselected pediatric hematology-oncology patients stratified based on their estimated renal function as decreased, normal or with ARC, and on their neutrophil count.Results: Thirty-two children provided a total of 51 meropenem and 76 piperacillin samples. On standard intermittent intravenous regimen, 67% of all trough plasma concentrations were below targeted concentrations. In neutropenic children with bacterial infection, all meropenem and 60% of piperacillin levels were below target. Nearly two-thirds of total samples came from children with ARC. In these patients, antimicrobial exposure was insufficient in 85% of cases (compared to 36% in the decreased or normal renal function groups), despite a dosage sometimes exceeding the maximum recommended daily dose. Under continuous infusion of piperacillin, only 8% of plasma levels were insufficient.Discussion: Intermittent administration of meropenem and piperacillin often fails to ensure sufficient concentration exposure in children treated for malignancies, even at maximal recommended daily dosage. This can in part be attributed to ARC. We recommend thorough assessment of renal function, resolute dosage adjustment, continuous infusion whenever possible and systematic therapeutic drug monitoring.


Author(s):  
L. Sadozai ◽  
S. Prot-Labarthe ◽  
O. Bourdon ◽  
S. Dauger ◽  
A. Deho

2022 ◽  
Vol Volume 15 ◽  
pp. 205-215
Author(s):  
Jin-Li Guo ◽  
Xian-Yan Yan ◽  
Qing-Li Zhao ◽  
Chao-Na Gao ◽  
Chen-Hui Wei ◽  
...  

Perfusion ◽  
2021 ◽  
pp. 026765912110638
Author(s):  
Tanya Perry ◽  
Brandon Henry ◽  
David S Cooper ◽  
Sundeep G Keswani ◽  
Kimberly S Burton ◽  
...  

Purpose Achieving effective anticoagulation during neonatal extracorporeal membrane oxygenation (ECMO) without increasing the risk of hemorrhage remains challenging. The use of antithrombin III (AT-III) for this purpose has been examined, but studies have been limited to intermittent bolus dosing. We aimed to evaluate the efficacy and safety of an institutionally developed AT-III continuous infusion protocol in neonates receiving ECMO for the treatment of congenital diaphragmatic hernia (CDH). Methods In this single center, retrospective study, all neonates with a CDH who received ECMO support during the study period were included. Data on anticoagulation labs and therapy, life-threatening bleeding, and circuit changes were analyzed. Results Eleven patients were divided into two groups: patients with AT-III continuous infusion ( n = 5) and without ( n = 6). There were no differences in the gestational age ( p = 0.29), sex ( p = 1.00), ECMO duration ( p = 0.59), or initial AT-III levels ( p = 0.76) between groups. Patients in the AT-III infusion group had on average 18.5% higher AT-III levels ( p < 0.0001). Patients receiving continuous AT-III infusions spent a significantly higher percentage of ECMO time within the therapeutic range, measured using anti-Factor Xa levels (64.9±4.2% vs. 29.1±8.57%, p = 0.008), and required fewer changes to the heparin infusion rate (6.48±0.88 vs 2.38±0.36 changes/day changes/day, p = 0.005). Multivariate analysis revealed continuous infusion of AT-III did not increase the rate of intracranial or surgical bleeding ( p = 0.27). Conclusion AT-III as a continuous infusion in CDH neonates on ECMO provides a decreased need to modify heparin infusion and more consistent therapeutic anticoagulation without increasing the risk of life-threatening bleeding.


2021 ◽  
Vol 50 (1) ◽  
pp. 281-281
Author(s):  
KHALID TAHER ◽  
Peter Johnson ◽  
Jamie Miller ◽  
Stephen Neely ◽  
Neha Gupta

2021 ◽  
Vol 50 (1) ◽  
pp. 609-609
Author(s):  
Caitlin Thomas ◽  
Julie Willmon ◽  
Tracey Smith ◽  
Eric Pyles

2021 ◽  
Vol 50 (1) ◽  
pp. 477-477
Author(s):  
Angad Sodhi ◽  
Joshua Arnold ◽  
Bruce Doepker ◽  
Jessica Elefritz ◽  
Gregory Eisinger ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document